Fiocruz: reference in health science and technology
Founded in 1900, the Oswaldo Cruz Foundation (Fiocruz) promotes health, generates scientific and technological knowledge and acts as citizenship agent. Under the Ministry of Health, the institution articulates social policies to a development model that allows the strengthening and consolidation of the Sistema Único de Saúde (SUS), ensuring greater public access to health. Known for its expertise in formulating strategies, product offerings, scientific and teaching activities, Fiocruz plays a strategic role in national development. All these achievements are the result of the performance of almost 13 thousand professionals, committed to the constant improvement of the public health system.
Its headquarters, as well as most of its units, is in Rio de Janeiro, a campus of 800,000 m². The Foundation has regional units and representative offices in 11 states. In Maputo, Mozambique’s capital, there is an office to articulate, monitor and evaluate health cooperation programs developed with African countries.
Bio-Manguinhos: 42 years of an Institute always making progress
Bio-Manguinhos is one of the 16 technical and scientific units of Fiocruz. In 2018, it delivered 118 million doses of vaccines to the National Immunization Program (NIP). In addition, 5.5 million bottles of biopharmaceuticals and 6.6 million of reagents for diagnosis were provided to other organs of the Ministry of Health. Since 2001, with the prequalification of the yellow fever vaccine by the World Health Organization (WHO), the laboratory acts in the international public market through the surplus of its production for SUS and has already supplied the vaccine to 74 countries. As a result of its portfolio of products and technological development, Bio-Manguinhos portfolio includes 31 products: 10 vaccines, 5 biopharmaceuticals, and 16 diagnostic reagents.
Bio-Manguinhos is an institution constantly growing and transforming. In later years, this movement became stronger. The unit has been expanding its infrastructure and will operate a new plant in Santa Cruz Industrial District, in Rio de Janeiro: the Industrial Complex of Health Biotechnology (CIBS). To increase the offer of vaccines and biopharmaceuticals for public health programs, the campus will house the New Center for Final Processing (NCPFI), as well as areas dedicated to quality assurance and control. The project will increase possibilities of partnerships focused on technology development and the Brazilian competitiveness in biotechnology. Also, in line with the technology development deconcentration policy and Fiocruz national expansion, a new campus is being implemented in Ceará at the Industrial Health Technology Center (PTIS), in the city of Eusébio. Bio will implement a new unit, and this unit will be the first industrial plant of the Institute outside Rio de Janeiro. The area will be dedicated to plant-based platform technology.